SBC Medical Group Holdings Inc., a Japanese owner and operator of aesthetic medical clinics with 258 affiliated clinics worldwide, has officially entered the U.S. market through a strategic investment in OrangeTwist, a U.S.-based medspa chain. This investment represents the initial phase of SBC's "full-scale" strategic expansion in the United States, where the medical aesthetics industry is projected to grow from $34 billion to $48 billion by 2030 according to company reports.
The partnership enables joint operations between the companies, leveraging synergies in both the U.S. and Asian markets. OrangeTwist operates 24 locations across six U.S. states, specializing in non-invasive aesthetic treatments including injectables, energy-based procedures, and regenerative treatments. SBC cited OrangeTwist's advanced management system—which integrates procurement, clinical workflows, and real-time KPI tracking—as providing operational consistency that supports scalable growth.
"OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine," said Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings. The companies plan to sell each other's services and products in both the U.S. and Japan while collaborating on new beauty products and services. Robert Settembro, CEO of OrangeTwist, stated that the partnership allows the company to "bring exceptional aesthetic experiences to more communities while leveraging SBC's global expertise."
This investment represents the first step in SBC's multiyear roadmap to establish a leading position in medical aesthetics and wellness markets through international expansion. The U.S. market presents significant growth opportunities driven by increasing demand for non-surgical treatments with minimal risk and downtime, as well as an aging population seeking aesthetic procedures. During 2026, SBC plans additional strategic investments and partnerships in both the U.S. and Southeast Asia, following its existing e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand.
Phase 2 of SBC's expansion plan, scheduled for 2027 and 2028, will focus on select acquisitions and joint ventures to accelerate growth and enhance competitive positioning. Phase 3, beginning in 2029, anticipates SBC achieving leadership positions in the U.S., Southeast Asia, and other key markets. The company's global network currently manages more than six million patient visits annually, providing a substantial foundation for this international growth strategy. The investment in OrangeTwist establishes SBC's initial foothold in the competitive U.S. medical aesthetics landscape while positioning both companies for expanded market reach through shared expertise and operational systems.
